UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

Journal of clinical oncology, 2013-10, Vol.31 (28), p.3509-3516

2013

Volltextzugriff (PDF)

The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study

European radiology, 2011-02, Vol.21 (2), p.281-290

2011

Volltextzugriff (PDF)

Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells

Journal of hepatology, 2012-07, Vol.57 (1), p.108-115

2012

Volltextzugriff (PDF)

Mitogenic Insulin Receptor-A Is Overexpressed in Human Hepatocellular Carcinoma due to EGFR-Mediated Dysregulation of RNA Splicing Factors

Cancer research (Chicago, Ill.), 2013-07, Vol.73 (13), p.3974-3986

2013

Volltextzugriff (PDF)

Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: A large multicenter AGEO study

Journal of hepatology, 2013-01, Vol.58 (1), p.81-88

2013

Volltextzugriff (PDF)

Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma

Clinical cancer research, 2009-09, Vol.15 (17), p.5445-5456

2009

Volltextzugriff (PDF)

Early and resectable HCC: Definition and validation of a subgroup of patients who could avoid liver transplantation

Journal of surgical oncology, 2015-06, Vol.111 (8), p.1007-1015

2015

Volltextzugriff (PDF)

Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies

Investigational new drugs, 2014-10, Vol.32 (5), p.1028-1035

2014

Volltextzugriff (PDF)

Technical feasibility and safety of laparoscopic right hepatectomy for hepatocellular carcinoma following sequential TACE–PVE: a comparative study

Surgical endoscopy, 2017-05, Vol.31 (5), p.2340-2349

2017

Volltextzugriff (PDF)

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

The lancet oncology, 2018-07, Vol.19 (7), p.940-952

2018

Volltextzugriff (PDF)

Effect of Prolonged Interferon Therapy on the Outcome of Hepatitis C Virus–Related Cirrhosis: A Randomized Trial

Clinical gastroenterology and hepatology, 2007-04, Vol.5 (4), p.502-507

2007

Volltextzugriff (PDF)

Traitement du carcinome hépatocellulaire avancé : une deuxième révolution avec l’immunothérapie

Biologie aujourd'hui, 2018, Vol.212 (3-4), p.85-87

2018

Volltextzugriff (PDF)

Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma

Liver international, 2015-10, Vol.35 (10), p.2203-2217

2015

Volltextzugriff (PDF)

Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib

European journal of cancer (1990), 2022-05, Vol.167, p.1-12

2022

Volltextzugriff (PDF)

Evidence-based integration of selective internal radiation therapy into the management of cholangiocarcinoma

Future oncology (London, England), 2014-11, Vol.10 (15s), p.89-92

2014

Volltextzugriff (PDF)

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

The lancet. Gastroenterology & hepatology, 2021-08, Vol.6 (8), p.649-658

2021

Volltextzugriff (PDF)

Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: A meta-analysis

Journal of hepatology, 2011-12, Vol.55 (6), p.1187-1194

2011

Volltextzugriff (PDF)

The Lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids

Hepatology (Baltimore, Md.), 2007-06, Vol.45 (6), p.1348-1354

2007

Volltextzugriff (PDF)

Contribution of biomarkers and imaging in the management of hepatocellular carcinoma

Clinics and research in hepatology and gastroenterology, 2011-06, Vol.35, p.S21-S30

2011

Volltextzugriff (PDF)

Metabolic syndrome, non alcoholic hepatic steatopathy and hepatocellular carcinoma: so dangerous liaisons

Bulletin de l'Académie nationale de médecine, 2014-12, Vol.198 (9), p.1653-63; discussion 1663-4

2014

Volltextzugriff (PDF)

Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography

Gastroenterology (New York, N.Y. 1943), 2019-09, Vol.157 (3), p.807-822

2019

Volltextzugriff (PDF)

Syndrome métabolique, stéatopathie hépatique non alcoolique (NASH) et carcinome hépatocellulaire : des liaisons bien dangereuses

Bulletin de l'Académie nationale de médecine, 2014-12, Vol.198 (9), p.1653-1664

2014

Volltextzugriff (PDF)

1 – 25 von 81

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(75)

Publikationsform

Sprache

Englisch
(67)
Französisch
(14)

Erscheinungsjahr

n.n

Thema

Humans
(43)
Science & Technology
(43)
Life Sciences & Biomedicine
(42)
Male
(28)
Female
(26)
Middle Aged
(24)
Gastroenterology & Hepatology
(20)
Aged
(17)
Life Sciences
(17)
Adult
(16)
Hepatocellular Carcinoma
(16)
Oncology
(16)
Biological And Medical Sciences
(14)
Medical Sciences
(14)
Liver Cancer
(12)
Gastroenterology. Liver. Pancreas. Abdomen
(11)
Liver Neoplasms - Drug Therapy
(11)
Prognosis
(11)
Tumors
(11)
Carcinoma, Hepatocellular - Drug Therapy
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial

The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study

Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells

Mitogenic Insulin Receptor-A Is Overexpressed in Human Hepatocellular Carcinoma due to EGFR-Mediated Dysregulation of RNA Splicing Factors

Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: A large multicenter AGEO study

Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma

Preoperative risk score for prediction of long-term outcomes after hepatectomy for intrahepatic cholangiocarcinoma: Report of a collaborative, international-based, external validation study

Early and resectable HCC: Definition and validation of a subgroup of patients who could avoid liver transplantation

Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies

Technical feasibility and safety of laparoscopic right hepatectomy for hepatocellular carcinoma following sequential TACE–PVE: a comparative study

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Effect of Prolonged Interferon Therapy on the Outcome of Hepatitis C Virus–Related Cirrhosis: A Randomized Trial

Traitement du carcinome hépatocellulaire avancé : une deuxième révolution avec l’immunothérapie

Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma

Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib

Evidence-based integration of selective internal radiation therapy into the management of cholangiocarcinoma

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: A meta-analysis

The Lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids

Contribution of biomarkers and imaging in the management of hepatocellular carcinoma

Metabolic syndrome, non alcoholic hepatic steatopathy and hepatocellular carcinoma: so dangerous liaisons

Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography

Syndrome métabolique, stéatopathie hépatique non alcoolique (NASH) et carcinome hépatocellulaire : des liaisons bien dangereuses

Suchergebnisse filtern